Hikma Pharmaceuticals PLC
LSE:HIK

Watchlist Manager
Hikma Pharmaceuticals PLC Logo
Hikma Pharmaceuticals PLC
LSE:HIK
Watchlist
Price: 1 950 GBX 4.17% Market Closed
Market Cap: 4.3B GBX
Have any thoughts about
Hikma Pharmaceuticals PLC?
Write Note

Hikma Pharmaceuticals PLC
Effect of Foreign Exchange Rates

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Hikma Pharmaceuticals PLC
Effect of Foreign Exchange Rates Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Effect of Foreign Exchange Rates CAGR 3Y CAGR 5Y CAGR 10Y
Hikma Pharmaceuticals PLC
LSE:HIK
Effect of Foreign Exchange Rates
-$9m
CAGR 3-Years
3%
CAGR 5-Years
-18%
CAGR 10-Years
-16%
GlaxoSmithKline PLC
LSE:GSK
Effect of Foreign Exchange Rates
-ÂŁ38m
CAGR 3-Years
28%
CAGR 5-Years
N/A
CAGR 10-Years
17%
AstraZeneca PLC
LSE:AZN
Effect of Foreign Exchange Rates
-$65m
CAGR 3-Years
-43%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Verona Pharma PLC
NASDAQ:VRNA
Effect of Foreign Exchange Rates
$1.9m
CAGR 3-Years
40%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Indivior PLC
LSE:INDV
Effect of Foreign Exchange Rates
$1m
CAGR 3-Years
-45%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Dechra Pharmaceuticals PLC
LSE:DPH
Effect of Foreign Exchange Rates
-ÂŁ400k
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Hikma Pharmaceuticals PLC
Glance View

Market Cap
4.3B GBX
Industry
Pharmaceuticals

Hikma Pharmaceuticals Plc engages in developing, manufacturing, and marketing branded and non-branded generic pharmaceutical products. The firm is focused on developing, manufacturing, marketing and selling of a broad range of generic, branded and in-licensed pharmaceuticals products in solid, semi-solid, liquid and injectable final dosage forms. The firm operates through three segments, such as Injectables, Generics and Branded. The Injectables business develops and manufactures generic injectable products, which are primarily used in hospitals. The Generics business develops and manufactures oral and other non-injectable generic products. The Branded business develops and manufactures branded generics and markets and sells in-licensed patented products in Middle East/North Africa (MENA). The Company’s products are sold in the retail and hospital markets. The company also markets its products in Canada, which includes approximately 25 sterile injectable products, three in-licenced ophthalmic products and a pipeline of seven additional products.

HIK Intrinsic Value
3 724.01 GBX
Undervaluation 48%
Intrinsic Value
Price

See Also

What is Hikma Pharmaceuticals PLC's Effect of Foreign Exchange Rates?
Effect of Foreign Exchange Rates
-9m USD

Based on the financial report for Jun 30, 2024, Hikma Pharmaceuticals PLC's Effect of Foreign Exchange Rates amounts to -9m USD.

What is Hikma Pharmaceuticals PLC's Effect of Foreign Exchange Rates growth rate?
Effect of Foreign Exchange Rates CAGR 10Y
-16%

Over the last year, the Effect of Foreign Exchange Rates growth was 40%. The average annual Effect of Foreign Exchange Rates growth rates for Hikma Pharmaceuticals PLC have been 3% over the past three years , -18% over the past five years , and -16% over the past ten years .

Back to Top